Literature DB >> 19105504

Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.

Elena Santagostino1, Maria Elisa Mancuso.   

Abstract

Modem treatment for hemophilic children is based on prophylaxis and immune tolerance induction (ITI). Both treatment regimens are based on frequent infusions at early ages, therefore an adequate venous access is essential. Peripheral veins represent the best option, however, different solutions, as central venous access devices (CVADs) and arteriovenous fistulae (AVFs), can be adopted if needed. CVADs have been used in hemophiliacs, however their survival is affected by infectious complications. Among CVADs, fully implantable devices are usually preferred to external lines due to a lower infectious risk. The limited survival of CVADs may have a relevant impact on treatment outcome, especially in case of ITI where treatment interruptions are counterproductive. To overcome such drawbacks, internal AVF has been considered as an alternative option owing to a lower rate of infectious complications. Moreover, AVF is easy to use in the home setting and well accepted by children. Possible complications not preventing AVF use are postoperative hematoma and transient symptoms of distal ischemia; one case of symptomatic thrombosis has been reported so far. Long-term complications include loss of patency, aneurysmatic dilatation and, rarely, limb dysmetria and a regular follow-up is mandatory to allow early remedial intervention. Surgical dismantlement of AVF is recommended as soon as transition to peripheral veins is possible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19105504      PMCID: PMC2652218          DOI: 10.2450/2008.0031-08

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  26 in total

Review 1.  Percutaneous catheterization of the subclavian vein in hemophiliac patients: report of 47 cases.

Authors:  B Fontes; A A Ferreira Filho; C R Carelli; W Fontes; D Birolini; R J Bevilacqua
Journal:  Int Surg       Date:  1992 Apr-Jun

2.  How to start prophylaxis.

Authors:  P Petrini
Journal:  Haemophilia       Date:  2003-05       Impact factor: 4.287

3.  The use of central venous catheters (portacaths) in children with haemophilia.

Authors:  C M Bollard; L R Teague; E W Berry; P A Ockelford
Journal:  Haemophilia       Date:  2000-03       Impact factor: 4.287

4.  Catheter-related deep venous thrombosis in children with hemophilia.

Authors:  J M Journeycake; C T Quinn; K L Miller; J L Zajac; G R Buchanan
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  Surveillance of infectious complications associated with central venous access devices in children with haemophilia.

Authors:  M D Tarantino; A Lail; S M Donfield; H Lynn; L Peddle; S Hunsberger; A D Shapiro
Journal:  Haemophilia       Date:  2003-09       Impact factor: 4.287

6.  A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia.

Authors:  V E Price; M Carcao; B Connolly; P Chait; A Daneman; M Temple; A M Stain; L Sung; H Al-Tralbosi; V S Blanchette
Journal:  J Thromb Haemost       Date:  2004-05       Impact factor: 5.824

7.  Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.

Authors:  Maria Elisa Mancuso; Pier Mannuccio Mannucci; Angelo Sartori; Andrea Agliardi; Elena Santagostino
Journal:  Br J Haematol       Date:  2008-04-10       Impact factor: 6.998

Review 8.  Central venous access devices in haemophilia.

Authors:  L A Valentino; B Ewenstein; R J Navickis; M M Wilkes
Journal:  Haemophilia       Date:  2004-03       Impact factor: 4.287

9.  Central venous line-related thrombosis in children: association with central venous line location and insertion technique.

Authors:  Christoph Male; Peter Chait; Maureen Andrew; Kim Hanna; Jim Julian; Lesley Mitchell
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

10.  Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study.

Authors:  Elena Santagostino; Alessandro Gringeri; Luisa Berardinelli; Claudio Beretta; Myrvet Muça-Perja; Pier Mannuccio Mannucci
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998

View more
  3 in total

1.  Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.

Authors:  Anthony K Chan; Jayanthi Alamelu; Chris Barnes; Ampaiwan Chuansumrit; May-Lill Garly; Rikke Medom Meldgaard; Guy Young
Journal:  Res Pract Thromb Haemost       Date:  2020-07-29

Review 2.  The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.

Authors:  Rivka Yatuv; Micah Robinson; Inbal Dayan-Tarshish; Moshe Baru
Journal:  Int J Nanomedicine       Date:  2010-09-07

3.  Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells.

Authors:  Jaichandran Sivalingam; Dimitar Kenanov; Hao Han; Ajit Johnson Nirmal; Wai Har Ng; Sze Sing Lee; Jeyakumar Masilamani; Toan Thang Phan; Sebastian Maurer-Stroh; Oi Lian Kon
Journal:  Mol Ther       Date:  2015-12-22       Impact factor: 11.454

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.